Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JDMVI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Lumretuzumab-ADC-Tb4-3
|
|||||
| Synonyms |
Lumretuzumab ADC Tb4 3
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2-8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Lumretuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Lumretuzumab-ADC-Tb4-3 linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.